Prior exposure to racial discrimination and patterns of acute parasympathetic nervous system responses to a race-related stress task among Black adults.

Black adults' prior exposure to racial discrimination may be associated with their acute parasympathetic reactivity to and recovery from a new race-related stressor. Existing analytical approaches to investigating this link obscure nuances in the timing, magnitude, and patterns of these acute parasympathetic nervous system (PNS) responses. In a re-analysis of a prior study, we utilize an hidden Markov model (HMM) approach to examine how prior experiences of racial discrimination are associated with intraindividual patterns of (1) physiological states of PNS activity and (2) patterns of and variability in transitions between these physiological states.

Health professionals' experiences and implications of a technology-focused service within a rehabilitation setting.

Purpose: Both demand and need for assistive technology (AT) are growing worldwide. However, ensuring an optimal fit between the person and AT is complex. With health professionals often being the "gatekeeper" to AT, it is imperative to understand their experiences of AT.

Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study.

Background: A pan-tuberculosis regimen that could be initiated without knowledge of drug susceptibility has been proposed as an objective of tuberculosis regimen development. We modelled the health and economic benefits of such a regimen and analysed which of its features contribute most to impact and savings.

Methods: We constructed a mathematical model of tuberculosis treatment parameterised with data from the published literature specific to three countries with a high tuberculosis burden (India, the Philippines, and South Africa).

Target regimen profiles for tuberculosis treatment.

Simpler, shorter, safer and more effective treatments for tuberculosis that are easily accessible to all people with tuberculosis are desperately needed. In 2016, the World Health Organization (WHO) developed target regimen profiles for the treatment of tuberculosis to make drug developers aware of both the important features of treatment regimens, and patient and programmatic needs at the country level. In view of recent ground-breaking advances in tuberculosis treatment, WHO has revised and updated these regimen profiles.